GeriMedRisk, a telemedicine geriatric pharmacology consultation service to address adverse drug events in long-term care: A stepped-wedge cluster randomized feasibility trial protocol (ISRCTN17219647)

被引：10

作者：

Ho J.M.-W. ^{[1
,2
,3
]}

Tung J. ^{[3
]}

Maitland J. ^{[4
]}

Mangin D. ^{[5
]}

Thabane L. ^{[6
]}

Pavlin J. ^{[7
]}

Alfonsi J. ^{[8
]}

Holbrook A. ^{[6
,9
]}

Straus S. ^{[10
,11
]}

Benjamin S. ^{[1
,3
]}

机构：

[1] Waterloo Regional Campus, McMaster University DeGroote School of Medicine, 10B Victoria St S, Kitchener, ON

[2] Schlegel Research Institute for Aging, 250 Laurelwood Drive, Waterloo, ON

[3] Grand River Hospital, 835 King St W, Kitchener, ON

[4] St. Joseph's Health Centre Guelph, 100 Westmount Ave, Guelph, ON

[5] Department of Family Medicine, McMaster University, 6th floor, 100 Main St W, Hamilton, ON

[6] Department of Health Research Methods, Evidence and Impact, McMaster University, H325, 50 Charlton Ave E, Hamilton, ON

[7] Lazaridis School of Business and Economics, Wilfrid Laurier University, 64 University Ave W, Waterloo, ON

[8] Ontario Telemedicine Network, 1100-105 Moatfield Drive, Toronto, ON

[9] Division of Clinical Pharmacology and Toxicology, McMaster University, 1280 Main St W, Hamilton, ON

[10] Li Ka Shing Knowledge Institute, St. Michael's Hospital, 30 Bond St Toronto, Toronto, ON

[11] Division of Geriatric Medicine, Department of Medicine, University of Toronto, 190 Elizabeth Street, R. Fraser Elliott Building, 3-805, Toronto, ON

来源：

Pilot and Feasibility Studies | / 4卷 / 1期

关键词：

Appropriate prescribing; Clinical trial; Cluster randomized controlled trial; Feasibility; Geriatrics; Telemedicine;

D O I：

10.1186/s40814-018-0300-x

中图分类号：

学科分类号：

摘要：

Background: Multimorbidity, polypharmacy, and older age predispose seniors to adverse drug events (ADE). Seniors with an ADE experience greater morbidity, mortality, and health care utilization compared to their younger counterparts. To mitigate and manage ADEs among this vulnerable population, we designed a geriatric pharmacology consultation service connecting clinicians with specialist physicians and pharmacists and will investigate the feasibility and acceptability of this complex intervention in the long-term care setting, prior to conducting a larger efficacy trial. Methods/Design: We will conduct a cluster randomized feasibility trial and qualitative analysis of GeriMedRisk among four long-term care homes in the Waterloo-Wellington region from May 1 to December 31, 2017. The primary outcome is the feasibility and acceptability of GeriMedRisk and the stepped-wedge cluster randomized controlled trial design. We hypothesize that GeriMedRisk is a feasible intervention and its potential to decrease falls and drug-related hospital visits can be evaluated with a stepped-wedge cluster randomized controlled trial design. Discussion: This mixed methods study will inform a larger efficacy trial of GeriMedRisk's ability to decrease adverse drug events among seniors in the long-term care setting. Ethics and dissemination: The Hamilton Integrated Research Ethics Board granted the approval for this study protocol 2812. We plan to disseminate the results of this study in peer-reviewed journals and also to our partners and stakeholders. Trial registration: ISRCTN clinical trials registry, ISRCTN17219647 (March 27, 2017). © The Author(s). 2018.

引用

共 32 条

[1] Wu C., Bell C.M., Wodchis W.P., Incidence and economic burden of adverse drug reactions among elderly patients in Ontario emergency departments: A retrospective study, Drug Saf, 35, 9, pp. 769-781, (2012)
[2] Budnitz D.S., Lovegrove M.C., Shehab N., Richards C.L., Emergency hospitalizations for adverse drug events in older Americans, N Engl J Med, 365, 21, pp. 2002-2012, (2011)
[3] Morgan S.G., Hunt J., Rioux J., Proulx J., Weymann D., Tannenbaum C., Frequency and cost of potentially inappropriate prescribing for older adults: A cross-sectional study, C Open, 4, 2, pp. E346-E351, (2016)
[4] Page A.T., Clifford R.M., Potter K., Schwartz D., Etherton-Beer C.D., The feasibility and effect of deprescribing in older adults on mortality and health: A systematic review and meta-analysis, Br J Clin Pharmacol, 82, 3, pp. 583-623, (2016)
[5] Ailabouni N.J., Nishtala P.S., Mangin D., Tordoff J.M., General practitioners' insight into deprescribing for the multimorbid older individual: A qualitative study, Int J Clin Pract, 70, 3, pp. 261-276, (2016)
[6] Ailabouni N.J., Nishtala P.S., Mangin D., Tordoff J.M., Challenges and enablers of deprescribing: A general practitioner perspective, PLoS One, 11, 4, (2016)
[7] Tracy C.S., Upshur R.E.G., MedsCheck: An opportunity missed, CMAJ, 178, 4, (2008)
[8] Farrell B., Pottie K., Rojas-Fernandez C.H., Bjerre L.M., Thompson W., Welch V., Methodology for developing deprescribing guidelines: Using evidence and GRADE to guide recommendations for deprescribing, PLoS One, 11, 8, (2016)
[9] Hogan D.B., Et al., Specialist physicians in geriatrics-report of the Canadian geriatrics society physician resource work group, Can. Geriatr. J, 15, 3, pp. 68-79, (2012)
[10] Dorsey E.R., Topol E.J., State of telehealth, N Engl J Med, 375, 2, pp. 154-161, (2016)

← 1 2 3 4 →